What Brown & Brown’s Index Removals Mean for Investors

The recent removal of Brown & Brown (BRO) from several Russell growth indices, including the Russell 1000 Growth and Russell 3000 Growth benchmarks, puts the stock in focus as index-tracking funds adjust their positions.

For you as an investor, this kind of index action often matters less for what it says about the underlying business and more for how it can influence trading flows and liquidity in the short term.

Brown & Brown’s share price has been volatile around the index removals, with a 1-day share price decline of 1.24% but a 30-day share price return of 17.95%. Over a longer period, the 1-year total shareholder return is down 36.17% and the 5-year total shareholder return is up 34.23%. This points to short term momentum against a weaker recent history.

If this kind of index driven move has you thinking more broadly about where to put fresh capital, it could be a good moment to scan for other ideas via the 19 top founder-led companies

Brown & Brown now trades below both analyst targets and some intrinsic value estimates after its index removals and recent swing in returns. Is this a simple discount, or is the market instead flagging real risks in the story?

Most Popular Narrative: 4.3% Undervalued

Brown & Brown’s most followed narrative pegs fair value at $71.50, slightly above the last close of $68.41. This sets the tone for a modest undervaluation story.

Brown & Brown's strategic focus on acquisitions, having completed 13 acquisitions with projected annual revenues of $36 million, could significantly enhance future revenue streams and market presence. This aligns with their goal of sustained revenue growth through expansion.

Want to see what sits behind that acquisition push and fair value gap? The narrative leans on steady revenue expansion, firm margins, and a richer earnings multiple. Curious which assumptions really carry the $71.50 figure and how long they are expected to hold?

Result: Fair Value of $71.50 (UNDERVALUED)

However, Brown & Brown’s story can shift quickly if pharmacy costs outpace medical costs and squeeze benefits margins, or if Florida insurance reforms are rolled back.

Next Steps

If this mix of short term pressure and longer term questions on Brown & Brown leaves you unsure, consider reviewing both sides of the story and weighing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Brown & Brown?

If Brown & Brown has sharpened your thinking, do not stop here. Use this momentum to line up the next wave of potential opportunities with a focused stock search.

• Target stronger value by checking companies that currently look attractively priced on fundamentals with the 44 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that appear to pair financial strength with measured risk using the 72 resilient stocks with low risk scores.
• Get ahead of the crowd by scanning a screener containing 19 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.